Ravel Biotechnology

Ravel.bio is a pioneering company in the biotechnology sector, focusing on the early detection of diseases through advanced molecular profiling and liquid biopsy technologies. The company serves healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the medical diagnostics and biotechnology markets. Ravel.bio's business model revolves around developing and commercializing cutting-edge diagnostic tools that enable early and accurate disease detection, particularly in oncology. The company generates revenue through the sale of its diagnostic platforms, licensing agreements, and partnerships with healthcare organizations. By leveraging expertise in molecular profiling, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), Ravel.bio aims to revolutionize the way diseases are detected and managed, ultimately improving patient outcomes.

Keywords: molecular profiling, liquid biopsy, early detection, oncology, diagnostics, healthcare, biotechnology, CTCs, ctDNA, EVs.